Search Results (21)
Click the Why column to see why an item matched the search.
Match | Type | Why |
---|
PharmVar GeneFocus: CYP2C9. | Academic Article |
Why?
|
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. | Academic Article |
Why?
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. | Academic Article |
Why?
|
CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. | Academic Article |
Why?
|
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. | Academic Article |
Why?
|
Efficiency of CYP2C9 genetic test representation for automated pharmacogenetic decision support. | Academic Article |
Why?
|
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. | Academic Article |
Why?
|
Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. | Academic Article |
Why?
|
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. | Academic Article |
Why?
|
Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project. | Academic Article |
Why?
|
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. | Academic Article |
Why?
|
Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. | Academic Article |
Why?
|
Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. | Academic Article |
Why?
|
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. | Academic Article |
Why?
|
Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. | Academic Article |
Why?
|